by Raynovich Rod | Dec 5, 2018 | Biopharmaceuticals, Macro
Update -4 After Close 12/7/18 Market Performance for the Week XBI down 7.8%, IBB down 6.6%, XLV down 5.2%, QQQ down 5.11%. Futures not looking good at 12:40a EST, NAZ down 0.82%. Global Growth worries mount; geopolitical turmoil reigns. Moderna (MRNA) IPO closes down...
by Raynovich Rod | Oct 10, 2018 | Biopharmaceuticals, Macro
Biotech Momentum Lost Technical Breakdown: XBI Near April Bottom but XLV Looks Good Market Looking for Growth from Large Cap Earnings 10 year auction has tepid demand at Yield of 3.225%, NASDAQ at 7602 own 1.75% (Prices as of mid-day 1:30 p EDT) Biotech momentum...
by Raynovich Rod | Oct 4, 2018 | Biopharmaceuticals, Macro
Update 10/5/18 Very Weak Technicals after Biotech Sell-Off NASDAQ market closed off the lows down 1.16% at 7788. Biotech ETF IBB down 1.15% just above 3 month support of 116. Biotech ETF XBI down 1.51% at 90.45 broke downtrend line and May support at 92. More losers...
by Raynovich Rod | Aug 13, 2018 | Biopharmaceuticals, Macro
Biotech Weekly Ending 8/18 …Five Day Performance The Biotech sector held on a turbulent geopolitical week favoring large caps. Amgen (AMGN) up 1.7%, Merck (MRK) up 3.6%, Regeneron (REGN) up 2.1%. Gilead Sciences (GILD) was off 6% on concerns it would lose market...
by Raynovich Rod | Mar 25, 2018 | Biopharmaceuticals, Macro
Sell-Off Gets Scary–NASDAQ Futures Still Down at 1:30A EDT 3/28 Double Bottom -Double Top on XBI and Testing February Lows at $87 Another Sell-Off=Tuesday Movers 3/27/18 Large Caps % Up-NONE FBT Down 3.23%, IBB Down 2.77% to $105.12, QQQ down 3.24%, XBI down...
by Raynovich Rod | Mar 19, 2018 | Biopharmaceuticals, Macro
Update-1… 3/19. Close is off the lows for Biotech Indices QQQ gap down to $167.10 also at SMA 50 XBI at SMA 50 bottom of channel at $91.89 XLV at $84 approaching February lows of $81 It is very difficult to find news or trends that can help us navigate this...
by Raynovich Rod | Feb 1, 2018 | Biopharmaceuticals, Macro
Profit Taking Hits Biotech Stocks Disruption Coming to Healthcare? Another Round of Sector Rotation? The biotech sector hit a wall after breaking through to new highs last week. The major news that sparked profit taking on Tuesday was that Amazon, Berkshire Hathaway...
by Raynovich Rod | Nov 29, 2017 | Biopharmaceuticals, Life Science ETF's and Mutual Funds, Macro
MegaCap Tech Stocks Take a Big Hit-Volatility Rising in a Sector Shift Market Rotation Supports Overall Market-S&P 500 Stable today up 17% YTD Sluggish Biotech Now Just a Market Performer With IBB up 17% YTD The booming tech sector sold off today with the XLK...
by Raynovich Rod | Nov 22, 2016 | Biopharmaceuticals, Macro
Update-1 November 28 Another nasty day for biotech A bit of a selloff in the market indices today with the NASDAQ down 0.58% and the S&P down 0.53%. The highly touted Russell 2000 (IWM) was down 1.3% after a 15 day rally. But the real wreck was in biotech with the...
by Raynovich Rod | Oct 26, 2016 | Biopharmaceuticals, Macro
Update-3… 10/28 9:30 am… No Relief From Earnings- Biotech Stocks Get Crushed By More Pricing Commentary on Earnings Calls Amgen (AMGN) down 11% on pipeline, revenue growth, Enbrel pricing concerns despite beat. Softer pricing environment from McKesson...